GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acrux Ltd (ASX:ACR) » Definitions » Price-to-Owner-Earnings

Acrux (ASX:ACR) Price-to-Owner-Earnings : (As of May. 12, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Acrux Price-to-Owner-Earnings?

As of today (2024-05-12), Acrux's share price is A$0.064. Acrux does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Acrux's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of Acrux was 258.00. The lowest was 2.67. And the median was 10.00.


ASX:ACR's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 35.03
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-12), Acrux's share price is A$0.064. Acrux's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.00. Therefore, Acrux's PE Ratio for today is At Loss.

As of today (2024-05-12), Acrux's share price is A$0.064. Acrux's EPS without NRI for the trailing twelve months (TTM) ended in was A$-0.00. Therefore, Acrux's PE Ratio without NRI for today is At Loss.

During the past 13 years, Acrux's highest PE Ratio without NRI was 88.10. The lowest was 0.00. And the median was 8.24.


Acrux Price-to-Owner-Earnings Historical Data

The historical data trend for Acrux's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acrux Price-to-Owner-Earnings Chart

Acrux Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Acrux Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acrux's Price-to-Owner-Earnings

For the Biotechnology subindustry, Acrux's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acrux's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acrux's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Acrux's Price-to-Owner-Earnings falls into.



Acrux Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Acrux's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.064/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acrux  (ASX:ACR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Acrux Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Acrux's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Acrux (ASX:ACR) Business Description

Industry
Traded in Other Exchanges
Address
103-113 Stanley Street, West Melbourne, Melbourne, VIC, AUS, 3003
Acrux Ltd is a pharmaceutical company dedicated to developing and commercializing generic transdermal and topical prescription pharmaceuticals. The group is formulating and developing a range of topical generic products by leveraging its skilled workforce, on-site laboratories, GMP manufacturing suite, and technical, clinical, and commercial experience to bring affordable products to market. Geographically, it has a presence in Australia; the United States; Europe, and other countries. The firm operates in a single segment and derives revenue from developing and commercializing pharmaceutical products that administer drugs topically. Its product pipeline products include Lenzetto, Evamist, Testosterone Topical Solution, and among others.